Table 3.
Module 3 GO and KEGG pathways analysis.
| ID | GO-term | Count | p-value | |
|---|---|---|---|---|
| Biological process | GO:0003012 | Muscle system process | 41 | 1.28E-49 |
| GO:0006936 | Muscle contraction | 39 | 4.87E-49 | |
| GO:0030049 | Muscle filament sliding | 24 | 1.43E-40 | |
| GO:0070252 | Actin-mediated cell contraction | 26 | 6.47E-38 | |
| GO:0030029 | Actin filament-based process | 31 | 1.35E-26 | |
| Molecular function | GO:0008092 | Cytoskeletal protein binding | 33 | 1.23E-21 |
| GO:0003779 | Actin binding | 25 | 1.28E-20 | |
| GO:0008307 | Structural constituent of muscle | 13 | 4.89E-18 | |
| GO:0051015 | Actin filament binding | 14 | 3.53E-13 | |
| GO:0005198 | Structural molecule activity | 19 | 9.42E-10 | |
| Cellular component | GO:0044449 | Contractile fiber part | 34 | 1.75E-42 |
| GO:0030017 | Sarcomere | 33 | 4.42E-42 | |
| GO:0099512 | Supramolecular fiber | 35 | 5.34E-25 | |
| GO:0031674 | I band | 19 | 3.53E-22 | |
| GO:0015629 | Actin cytoskeleton | 26 | 3.53E-22 | |
| Pathways | Description | |||
| KEGG pathways | hsa05414 | Dilated cardiomyopathy (DCM) | 14 | 2.95E-16 |
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | 13 | 1.66E-15 | |
| hsa04261 | Adrenergic signaling in cardiomyocytes | 15 | 1.66E-15 | |
| hsa04260 | Cardiac muscle contraction | 11 | 1.03E-12 | |
| hsa04020 | Calcium signaling pathway | 12 | 2.48E-10 |